

30 May 2023

ASX Code: MXC

LSE Code: MXC

## Dispatch of General Meeting Documents

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')** would like to advise that it has commenced distribution of the accompanying letter to shareholders, advising them of the details of the General Meeting of shareholders to be held at 4:00pm (AWST) Thursday, 29 June 2023, at 1202 Hay Street West Perth Western Australia 6005.

Also being dispatched to shareholders today is the Notice of General Meeting for the above meeting.

-Ends-

**Authorised for release by the board of Directors, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**MGC Pharmaceuticals Ltd**

Arron Canicais / Rowan Harland  
Joint Company Secretaries  
+61 8 6382 3390  
[info@mgcpharma.co.uk](mailto:info@mgcpharma.co.uk)

**UK Brokers**

**Peterhouse Capital**

Charles Goodfellow / Lucy Williams / Duncan Vasey  
+44 207 469 0930  
[cg@peterhousecap.com](mailto:cg@peterhousecap.com) / [lw@peterhousecap.com](mailto:lw@peterhousecap.com)

**UK Brokers**

**Oberon Capital**

Aimee McCusker / Adam Pollock  
+44 203 179 5300  
[aimeemccusker@oberoninvestments.com](mailto:aimeemccusker@oberoninvestments.com)  
[adampollock@oberoninvestments.com](mailto:adampollock@oberoninvestments.com)

**UK IR/PR Advisers**

**IFC Advisory**

Graham Herring / Tim Metcalfe / Zach Cohen  
+44 203 934 6630  
[mgcpharma@investor-focus.co.uk](mailto:mgcpharma@investor-focus.co.uk)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

*Follow us through our social media channels:*

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC\_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc\_pharma

30 May 2023

**LETTER TO SHAREHOLDERS – UPCOMING GENERAL MEETING**

Dear Shareholder,

**MGC Pharmaceuticals Ltd (Company or MGC Pharma)** advises that it is convening a General Meeting of shareholders at 4:00pm (AWST) on Thursday the 29<sup>th</sup> of June 2023 at 1202 Hay Street, West Perth, Australia 6005.

The Company is continuing to monitor the impact of the COVID-19 virus in Western Australia and follow guidance from the Federal and State Governments. Having considered the current circumstances, the directors have made the decision that a physical meeting will be held. Accordingly, Shareholders will be able to attend the Meeting in person, subject to them complying with any Government orders relating to COVID-19 in place at the time that the meeting is held.

In accordance with the Corporations Act 2001 the Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has requested a hard copy.

A copy of the Company's Notice of Meeting released to the ASX on 30 May 2023 is available to view on the Company's Website at <https://mgcpharma.co.uk/investors/asx/announcements>.

The directors strongly encourage all shareholders to lodge a directed proxy form prior to the meeting. If you have provided an email address and have elected to receive electronic communications from the Company, you will also be sent an email with a link to an electronic copy of the important meeting documents.

If you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience. Proxy votes can be lodged with the Company's Share Registry, Computershare Investor Services Pty Ltd online by using the following options:

Online	At <a href="http://www.investorvote.com.au">www.investorvote.com.au</a>
By mail	Share Registry – Computershare Investor Services Pty Limited, GPO Box 242, Melbourne Victoria 3001, Australia
By fax	1800 783 447 (within Australia) +61 3 9473 2555 (outside Australia)
By mobile	Scan the QR code on your proxy form and follow the prompts
Custodian Voting	For Intermediary Online subscribers only (custodians) please visit <a href="http://www.intermediaryonline.com">www.intermediaryonline.com</a> to submit your voting intentions

Yours sincerely,

**On behalf of MGC Pharmaceuticals Ltd,**

**Rowan Harland**  
Company Secretary